Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (23)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Sarvesvaran, J.
Right arrow Articles by Keith, W.N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sarvesvaran, J.
Right arrow Articles by Keith, W.N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Carcinogenesis, Vol. 20, No. 8, 1649-1652, August 1999
© 1999 Oxford University Press

Short Communications

Is small cell lung cancer the perfect target for anti-telomerase treatment?

Joseph Sarvesvaran, James J. Going1, Robert Milroy2, Stanley B. Kaye and W.Nicol Keith3

CRC Department of Medical Oncology, University of Glasgow, CRC Beatson Laboratories, Garscube Estate, Switchback Road, Glasgow G61 1BD,
1 Glasgow University Department of Pathology, Royal Infirmary, Glasgow and
2 Department of Respiratory Medicine, Stobhill Hospital, Glasgow, UK

Small cell lung cancer (SCLC) is common in men and women, has a very poor prognosis, and is therefore a major cause of premature mortality. As such, any prospects for improved therapy are of great significance. The promise of telomerase as a therapeutic target is now close to realization with extremely encouraging preclinical studies aimed at the RNA component (hTR) of telomerase. The rational integration of telomerase therapeutics into clinical trials will therefore require tumours to be well characterized for hTR expression. Despite the large number of cancer types now characterized for telomerase or telomerase component gene expression, only a handful of SCLC samples have been analysed. Given the major clinical problem with treating SCLC, we specifically set out to address the issue of hTR expression in neuroendocrine tumours. Our study covers 91 pulmonary neuroendocrine tumours (62 SCLC and 29 carcinoid tumours). We present data to show that upregulation of the RNA component of telomerase occurs in 98% of human SCLCs. Interestingly, the less aggressive carcinoid tumours of the lung had a significantly lower frequency of hTR expression (P < 0.01). Importantly, we compare hTR expression in this series to the well characterized biological targets p53 and BCL2, and show hTR to be expressed more frequently. Therapies directed at the RNA component of human telomerase are in active development and these data show SCLC to be a prime target for such therapies.

Abbreviations: hTR, human telomerase RNA component gene; SCLC, small cell lung cancer.

3 To whom correspondence should be addressed Email: n.keith{at}beatson.gla.ac.uk


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cancer Res.Home page
A. E. Bilsland, A. Merron, G. Vassaux, and W. N. Keith
Modulation of Telomerase Promoter Tumor Selectivity in the Context of Oncolytic Adenoviruses
Cancer Res., February 1, 2007; 67(3): 1299 - 1307.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
Y. Nishio, K. Nakanishi, Y. Ozeki, S.-X. Jiang, T. Kameya, A. Hebisawa, M. Mukai, W. D. Travis, T. J. Franks, and T. Kawai
Telomere Length, Telomerase Activity, and Expressions of Human Telomerase mRNA Component (hTERC) and Human Telomerase Reverse Transcriptase (hTERT) mRNA in Pulmonary Neuroendocrine Tumors
Jpn. J. Clin. Oncol., January 1, 2007; 37(1): 16 - 22.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. E. Bilsland, K. Stevenson, S. Atkinson, W. Kolch, and W. N. Keith
Transcriptional Repression of Telomerase RNA Gene Expression by c-Jun-NH2-Kinase and Sp1/Sp3
Cancer Res., February 1, 2006; 66(3): 1363 - 1370.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. Zaffaroni, R. Villa, U. Pastorino, R. Cirincione, M. Incarbone, M. Alloisio, M. Curto, S. Pilotti, and M. G. Daidone
Lack of Telomerase Activity in Lung Carcinoids Is Dependent on Human Telomerase Reverse Transcriptase Transcription and Alternative Splicing and Is Associated with Long Telomeres
Clin. Cancer Res., April 15, 2005; 11(8): 2832 - 2839.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
B. Ogretmen, D. Schady, J. Usta, R. Wood, J. M. Kraveka, C. Luberto, H. Birbes, Y. A. Hannun, and L. M. Obeid
Role of Ceramide in Mediating the Inhibition of Telomerase Activity in A549 Human Lung Adenocarcinoma Cells
J. Biol. Chem., June 29, 2001; 276(27): 24901 - 24910.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
B. Ogretmen, J. M. Kraveka, D. Schady, J. Usta, Y. A. Hannun, and L. M. Obeid
Molecular Mechanisms of Ceramide-mediated Telomerase Inhibition in the A549 Human Lung Adenocarcinoma Cell Line
J. Biol. Chem., August 24, 2001; 276(35): 32506 - 32514.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.